Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR104 + filgrastim
- Development stage
- Unknown
- Lead developer
- Proacta
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
PR104 + filgrastim is a combination therapy consisting of **PR104**, a hypoxia-activated prodrug, and **filgrastim**, a recombinant granulocyte colony-stimulating factor. PR104 is a phosphate ester that is rapidly converted to PR-104A, which is then enzymatically reduced to cytotoxic nitrogen mustards under hypoxic conditions, causing DNA cross-linking and cell death, especially in hypoxic tumor microenvironments[1]. Filgrastim stimulates the production of neutrophils to mitigate the myelosuppressive effects of cytotoxic chemotherapy, such as PR104, reducing risks associated with neutropenia[2][4][5]. This combination has been investigated to determine the maximum tolerated dose and safety in patients with solid tumors[2][4][5].
- Other names
- PR104PR-104PR 104filgrastimG-CSFgranulocyte colony-stimulating factor
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on PR104 + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR104 + filgrastim.